Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Brain Cancer

Expert Opinion / Cases · March 16, 2021

Glial/Glioneuronal Neoplasm With BRAF V600E Mutation

Written by
Martin C. Tom MD

 

Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Ana Misir Krpan

    Mar 17, 2021

    I would recommend observation and close follow-up.

  • Pieromaria Bianchi

    Mar 19, 2021

    No adjuvant therapy, just periodical MRI control. I would suggest bimonthly MRI at least for the first year

  • Simon Khagi

    Mar 19, 2021

    Serial MRI surveillance every 2-3 months. I would also recommend NGS of the tumor specimen. 

  • Fabio Trippa

    Mar 20, 2021

    I agree with previous comments. At this time I would recommend close follow-up.

  • Minesh Mehta

    Mar 22, 2021

    Glioneuronal tumors occur more commonly in children than in adults, are often lower grade, frequently associated with seizures, and a significant number are characterized by BRAFV600E dysregulation.  The exact management following surgery remains ill-defined; a recent report from St. Jude's suggested that "high-risk" can be defined as diffuse astrocytic histology and/or midbrain/thalamic location" and speculated that post-operative radiotherapy might be beneficial in such a situation.
    This patient does not have such high risk features and observation with surveillance is a very reasonable strategy.

  • ruofan huang

    Mar 24, 2021

    observation

  • Amir Anvari

    May 21, 2021

    Close follow up

  • Martin Tom MD

    Martin C. Tom MD

    Jun 25, 2021

    Update:

    The patient was observed and 2 month MRI brain was read as stable. However, repeat MRI 2 months later showed progression with a larger area of enhancement measuring 18 x 16 x 16 mm with increased rCBV, without significant surrounding edema. How would you proceed with management now?


  • Dron Gauchan

    Nov 28, 2022

    You should probably use Braf and Mek inhibitors

  • Jun 24, 2024

    Pending Moderator approval.
    Delete

Further Reading